Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase NA 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 4Genitourinary 3Gastrointestinal 3Dermatologic 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 2Breast 2Other solid neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Medulloblastoma 2Carcinoma, Basal Cell 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × sonidegib × Dermatologic × Clear all
NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Active not recruiting
36 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT00880308 2020-12-19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
103 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

NCT01208831 2020-12-19

An East Asian Study of LDE225

Novartis

Phase 1 Completed
45 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡